RxDoctor Payments Data

Steven Lugo, MD

Adult Medicine · Scottsdale, AZNPI 1356451934

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Amgen at 40.6% of the total. That places this record below the midpoint for adult medicine clinicians in AZ, where the typical reported total is $190.

$190in general payments, 2019–2025

Across 8 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$77
  • GSK$63
  • Pfizer$23
  • AstraZeneca$15
  • Novo Nordisk$11

What the payments were for

  • Food & beverage$190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen4$77
GSK1$63
Pfizer1$23
AstraZeneca1$15
Novo Nordisk1$11

How this compares

$190 in reported general payments places this provider in the 50th percentile of 35 adult medicine providers in Arizona.

See all adult medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$177,504
Medicare patients
582
Services billed
4,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide108$125,620
EliquisApixaban75$90,510
FarxigaDapagliflozin Propanediol44$42,640
JanuviaSitagliptin Phosphate26$35,363
RybelsusSemaglutide24$25,883
Tresiba Flextouch U-100Insulin Degludec38$21,900
JardianceEmpagliflozin11$18,762
MyrbetriqMirabegron27$18,609
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$16,105
Breo ElliptaFluticasone/Vilanterol28$15,998
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$13,666
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$12,163
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,844
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$7,367
Incruse ElliptaUmeclidinium Bromide21$7,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$11$151,503132 claims
PfizerEliquis$23$90,51075 claims
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta$63$48,85597 claims
AstraZenecaFarxiga$15$42,64044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 35 adult medicine providers in Arizona.

Other adult medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →